TAC-话题@MedSci

#TAC#

115篇内容 | 2658人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2033744, encodeId=e1ed2033e44cf, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=新药研发利器PROTAC技术全面解析：原理，历史，优势，设计，挑战，机遇与下一代PROTAC技术, objectType=article, longId=216449, objectId=b3ec21644961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3ec21644961, replyNumber=0, likeNumber=72, createdTime=2022-04-18, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3ec21644961, moduleTitle=新药研发利器PROTAC技术全面解析：原理，历史，优势，设计，挑战，机遇与下一代PROTAC技术, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3ec21644961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033731, encodeId=390d2033e3113, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Eur Radiol：合并累及血管的肝细胞肝癌患者经姑息TACE治疗效果如何？, objectType=article, longId=205664, objectId=7fb72056643d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fb72056643d, replyNumber=0, likeNumber=99, createdTime=2021-02-10, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fb72056643d, moduleTitle=Eur Radiol：合并累及血管的肝细胞肝癌患者经姑息TACE治疗效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fb72056643d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033735, encodeId=585a2033e3535, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=NEJM：Pegcetacoplan对于阵发性睡眠性血红蛋白尿的治疗效果优于Eculizumab, objectType=article, longId=208673, objectId=25e82086e3fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25e82086e3fe, replyNumber=0, likeNumber=80, createdTime=2022-01-25, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25e82086e3fe, moduleTitle=NEJM：Pegcetacoplan对于阵发性睡眠性血红蛋白尿的治疗效果优于Eculizumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25e82086e3fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033741, encodeId=185a2033e410a, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Hepatol Int: 前瞻性研究评估TACE单纯使用碘油对比TACE使用碘油联合可降解的淀粉微球(DSM)治疗肝细胞癌的疗效, objectType=article, longId=213475, objectId=ae672134e56d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae672134e56d, replyNumber=0, likeNumber=52, createdTime=2021-08-29, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae672134e56d, moduleTitle=Hepatol Int: 前瞻性研究评估TACE单纯使用碘油对比TACE使用碘油联合可降解的淀粉微球(DSM)治疗肝细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae672134e56d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033733, encodeId=36662033e337f, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=欧洲接受CAR-T疗法Ciltacabtagene Autoleucel（Cilta-cel）的加速评估，以治疗多发性骨髓瘤, objectType=article, longId=206689, objectId=8a6220668996, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a6220668996, replyNumber=0, likeNumber=78, createdTime=2021-09-14, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a6220668996, moduleTitle=欧洲接受CAR-T疗法Ciltacabtagene Autoleucel（Cilta-cel）的加速评估，以治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a6220668996)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033732, encodeId=ad402033e323b, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=J Clin Oncol：Abatacept协同刺激阻断可明显有效预防急性GVHD！, objectType=article, longId=206294, objectId=1ff32062949d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ff32062949d, replyNumber=0, likeNumber=131, createdTime=2021-02-02, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ff32062949d, moduleTitle=J Clin Oncol：Abatacept协同刺激阻断可明显有效预防急性GVHD！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ff32062949d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033739, encodeId=9c682033e3976, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=J Med Chem: 双PROTAC来了：我国学者首次提出双重靶向降解（Dual PROTACs）药物设计新概念, objectType=article, longId=212128, objectId=c3ae212128cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3ae212128cd, replyNumber=0, likeNumber=101, createdTime=2021-08-10, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3ae212128cd, moduleTitle=J Med Chem: 双PROTAC来了：我国学者首次提出双重靶向降解（Dual PROTACs）药物设计新概念, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3ae212128cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033728, encodeId=73f22033e28d9, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=C3肾小球病的治疗或迎重大突破！Iptacopan显示出希望, objectType=article, longId=202562, objectId=125620256210, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=125620256210, replyNumber=0, likeNumber=64, createdTime=2020-12-23, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=125620256210, moduleTitle=C3肾小球病的治疗或迎重大突破！Iptacopan显示出希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=125620256210)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033730, encodeId=abeb2033e305d, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Euro Radio:利用CT纹理分析来发现肝细胞肝癌TACE治疗后的反应！, objectType=article, longId=204718, objectId=06e3204e180d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06e3204e180d, replyNumber=0, likeNumber=57, createdTime=2021-02-18, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06e3204e180d, moduleTitle=Euro Radio:利用CT纹理分析来发现肝细胞肝癌TACE治疗后的反应！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06e3204e180d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033729, encodeId=d05d2033e2942, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Clin Cancer Res：JAK1抑制剂Itacitinib可有效预防CAR T细胞疗法引发的细胞因子释放综合征, objectType=article, longId=204517, objectId=6bae20451ef6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bae20451ef6, replyNumber=0, likeNumber=58, createdTime=2021-04-16, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bae20451ef6, moduleTitle=Clin Cancer Res：JAK1抑制剂Itacitinib可有效预防CAR T细胞疗法引发的细胞因子释放综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bae20451ef6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033723, encodeId=1ab42033e2390, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=获得1亿美元融资后，荣昌生物的融合蛋白TACI-Fc治疗红斑狼疮获得FDA快速通道指定, objectType=article, longId=192487, objectId=54e819248eed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54e819248eed, replyNumber=0, likeNumber=62, createdTime=2020-10-24, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54e819248eed, moduleTitle=获得1亿美元融资后，荣昌生物的融合蛋白TACI-Fc治疗红斑狼疮获得FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54e819248eed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033727, encodeId=e2012033e2768, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=EHA 2020：III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著, objectType=article, longId=195820, objectId=4ad419582055, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ad419582055, replyNumber=0, likeNumber=87, createdTime=2020-07-12, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ad419582055, moduleTitle=EHA 2020：III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ad419582055)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033724, encodeId=90342033e24ab, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=辉瑞TFPI抗体Marstacimab用于血友病治疗，在国内将开展临床试验, objectType=article, longId=194676, objectId=74451946e614, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74451946e614, replyNumber=0, likeNumber=75, createdTime=2020-08-27, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74451946e614, moduleTitle=辉瑞TFPI抗体Marstacimab用于血友病治疗，在国内将开展临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74451946e614)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033726, encodeId=72052033e2604, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, objectType=article, longId=195490, objectId=a38e195490b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38e195490b9, replyNumber=0, likeNumber=27, createdTime=2021-02-13, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38e195490b9, moduleTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a38e195490b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033725, encodeId=bb9b2033e2597, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=UCB以2.7亿美元收购Engage公司，及其手持口腔吸入式癫痫急救药物Staccato Alprazolam, objectType=article, longId=195460, objectId=3cd41954601e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cd41954601e, replyNumber=0, likeNumber=61, createdTime=2020-09-10, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cd41954601e, moduleTitle=UCB以2.7亿美元收购Engage公司，及其手持口腔吸入式癫痫急救药物Staccato Alprazolam, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cd41954601e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033719, encodeId=2ca72033e1952, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功, objectType=article, longId=185945, objectId=1f6e1859452d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f6e1859452d, replyNumber=0, likeNumber=88, createdTime=2020-11-14, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f6e1859452d, moduleTitle=Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f6e1859452d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033721, encodeId=6b162033e219f, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=2020 NTAC/CDC建议：潜伏性结核感染的治疗指南, objectType=article, longId=188776, objectId=5e56188e764d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e56188e764d, replyNumber=0, likeNumber=28, createdTime=2020-03-22, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e56188e764d, moduleTitle=2020 NTAC/CDC建议：潜伏性结核感染的治疗指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e56188e764d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033722, encodeId=f6a82033e2273, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=2020 ITAC-CME临床实践指南：直接口服抗凝剂时期癌症相关血栓形成的管理, objectType=article, longId=188966, objectId=89891889661c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89891889661c, replyNumber=0, likeNumber=28, createdTime=2020-05-16, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89891889661c, moduleTitle=2020 ITAC-CME临床实践指南：直接口服抗凝剂时期癌症相关血栓形成的管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89891889661c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033713, encodeId=30b62033e1359, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=Cancer：TACE联合索拉非尼延长晚期肝癌患者寿命, objectType=article, longId=179320, objectId=23901e93204c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23901e93204c, replyNumber=0, likeNumber=43, createdTime=2020-05-07, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23901e93204c, moduleTitle=Cancer：TACE联合索拉非尼延长晚期肝癌患者寿命, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23901e93204c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2033714, encodeId=2e702033e140b, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, objectTitle=葛兰素史克（GlaxoSmithKline）将在所有市场上召回可能被污染Zantac（雷尼替丁）, objectType=article, longId=180872, objectId=46601808e2b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46601808e2b7, replyNumber=0, likeNumber=62, createdTime=2020-04-23, rootId=0, userName=grace5700, userId=b05b180, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46601808e2b7, moduleTitle=葛兰素史克（GlaxoSmithKline）将在所有市场上召回可能被污染Zantac（雷尼替丁）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46601808e2b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TAC

2020-05-29

grace5700 (审核中...)

前往app查看评论内容

#TAC#

新药研发利器PROTAC技术全面解析：原理，历史，优势，设计，挑战，机遇与下一代PROTAC技术

2022-04-18

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Eur Radiol：合并累及血管的肝细胞肝癌患者经姑息TACE治疗效果如何？

2021-02-10

grace5700 (审核中...)

前往app查看评论内容

#TAC#

NEJM：Pegcetacoplan对于阵发性睡眠性血红蛋白尿的治疗效果优于Eculizumab

2022-01-25

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Hepatol Int: 前瞻性研究评估TACE单纯使用碘油对比TACE使用碘油联合可降解的淀粉微球(DSM)治疗肝细胞癌的疗效

2021-08-29

grace5700 (审核中...)

前往app查看评论内容

#TAC#

欧洲接受CAR-T疗法Ciltacabtagene Autoleucel（Cilta-cel）的加速评估，以治疗多发性骨髓瘤

2021-09-14

grace5700 (审核中...)

前往app查看评论内容

#TAC#

J Clin Oncol：Abatacept协同刺激阻断可明显有效预防急性GVHD！

2021-02-02

grace5700 (审核中...)

前往app查看评论内容

#TAC#

J Med Chem: 双PROTAC来了：我国学者首次提出双重靶向降解（Dual PROTACs）药物设计新概念

2021-08-10

grace5700 (审核中...)

前往app查看评论内容

#TAC#

C3肾小球病的治疗或迎重大突破！Iptacopan显示出希望

2020-12-23

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Euro Radio:利用CT纹理分析来发现肝细胞肝癌TACE治疗后的反应！

2021-02-18

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Clin Cancer Res：JAK1抑制剂Itacitinib可有效预防CAR T细胞疗法引发的细胞因子释放综合征

2021-04-16

grace5700 (审核中...)

前往app查看评论内容

#TAC#

获得1亿美元融资后，荣昌生物的融合蛋白TACI-Fc治疗红斑狼疮获得FDA快速通道指定

2020-10-24

grace5700 (审核中...)

前往app查看评论内容

#TAC#

EHA 2020：III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著

2020-07-12

grace5700 (审核中...)

前往app查看评论内容

#TAC#

辉瑞TFPI抗体Marstacimab用于血友病治疗，在国内将开展临床试验

2020-08-27

grace5700 (审核中...)

前往app查看评论内容

#TAC#

EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept

2021-02-13

grace5700 (审核中...)

前往app查看评论内容

#TAC#

UCB以2.7亿美元收购Engage公司，及其手持口腔吸入式癫痫急救药物Staccato Alprazolam

2020-09-10

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功

2020-11-14

grace5700 (审核中...)

前往app查看评论内容

#TAC#

2020 NTAC/CDC建议：潜伏性结核感染的治疗指南

2020-03-22

grace5700 (审核中...)

前往app查看评论内容

#TAC#

2020 ITAC-CME临床实践指南：直接口服抗凝剂时期癌症相关血栓形成的管理

2020-05-16

grace5700 (审核中...)

前往app查看评论内容

#TAC#

Cancer：TACE联合索拉非尼延长晚期肝癌患者寿命

2020-05-07

grace5700 (审核中...)

前往app查看评论内容

#TAC#

葛兰素史克（GlaxoSmithKline）将在所有市场上召回可能被污染Zantac（雷尼替丁）

2020-04-23

科室
- - 订阅+
  - 更多科室
工具
服务